The different roles of toll-like receptors in oncotherapy
https://doi.org/10.17650/1726-9784-2019-18-3-15-22
Abstract
The review considers and analyzes the literature data on the functions of the toll-like receptor family (TLR) in the development of malignant process. The structure of TLR, mechanisms of intracellular signal transduction, specific ligands antagonists and agonists of TLR are briefly reflected. Effects of various TLR from the point of view of influence on tumor growth and reactions of cellular immunity are given. The ambiguous results of experimental and clinical application of agonists and antagonists of TLR are compared. It is concluded that it is necessary to obtain additional information with the agonists of TLR at the stages of preclinical study.
About the Authors
E. M. Treshalina
N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia
Russian Federation
24 Kashyrskoe Shosse, Moscow 115478.
Russian Federation
24 Kashyrskoe Shosse, Moscow 115478.
I. N. Mikhaylova
N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia
Russian Federation
24 Kashyrskoe Shosse, Moscow 115478.
Russian Federation
24 Kashyrskoe Shosse, Moscow 115478.
M. V. Kiselevskiy
N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia
Russian Federation
24 Kashyrskoe Shosse, Moscow 115478.
Russian Federation
24 Kashyrskoe Shosse, Moscow 115478.
References
1. Chikileva I.O., Karaulov A.V., Anisimova N.Yu., Kiselevskiy M.V. The dual role of toll-like receptors in the regulation of the antitumor response. Immunology = Immunologiya 2010;(1):52—5. (In Russ.).
2. Alvarado A.G., Thiagarajan P.S., Mulkearns-Hubert E.E. et al. Glioblastoma cancer stem cells evade innate immune suppression of self-renewal through reduced TLR4 expression. Cell Stem Cell 2017;20(4):450—61. DOI: https://doi.org/10.1016/j.stem.2016.12.001.
3. Chen D., Wu M., Li Y. et al. Targeting BMI1 + cancer stem cells overcomes chemoresistance and inhibits metastases in squamous cell carcinoma. Cell Stem Cell 2017;20(5):621 —34. DOI: 10.1016/j.stem.2017.02.003.
4. Jin M.S., Lee J.-O. Structures of the toll-like receptor family and its ligand complexes. Immunity 2008;29:182-91. DOI: 10.1016/j.immuni.2008.07.007.
5. Chistyakov D.V., Aleshin S., Sergeeva M.G. and Reiser G. Regulation of peroxisome proliferator-activated receptor p/5 expression and activity levels by toll-like receptor agonists and MAP kinase inhibitors in rat astrocytes. J Neurochem 2014;130(4):563—74. DOI: 10.1111/jnc.12757.
6. Randhawa A.K., Hawn T.R. Toll-like receptors: their roles in bacterial recognition and respiratory infections. Expert Rev Anti Infect Ther 2008;6(4):479-95. DOI: 10.1586/14787210.6.4.479.
7. Merline R., Moreth K., Beckmann J. et al. Signaling by the matrix proteoglycan decorin controls inflammation and cancer through PDCD4 and microRNA-21. Sci Signal 2011;4(199):75. DOI: 10.1126/scisignal.2001868.
8. Gharbaran R. Advances in the molecular functions of syndecan-1 (SDC1/CD138) in the pathogenesis of malignancies. Crit Rev Oncol Hematol 2015;94(1):1-17. DOI: 10.1016/j.critrevonc.2014.12.003.
9. Shi X., Liang W., Yang W. et al. Decorin is responsible for progression of non-small-cell lung cancer by promoting cell proliferation and metastasis. Tumour Biol 2015;36(5):3345—54. DOI: 10.1007/s13277-014-2968-8.
10. Suhovskih A.V., Grigor’eva E.V. Tissue-specificity of proteoglycans expression in different cancers.. Uspekhi molekulyarnoy onkologii = Advances in molecular oncology 2016;(3):53—60. (In Russ.).
11. Sokolova T.M., Poloskov V.V., Burova O.S. et al. Action interferons and IFN-inductors on TLR/RLRs genes expression and differentiation of tumor cell lines THP-1 and HCT-116. Rossiysky Bioterapevtichesky Zhurnal = Russian Journal of Biotherapy 2016;15(3):28—33 (In Russ.).
12. He W., Liu Q., Wang L. et al. TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol 2007;(44):2850-9. DOI: 10.1016/j.molimm.2007.01.022.
13. Bertin S., Pierrefite-Carle V. Autophagy and toll-like receptors: a new link in cancer cells. Autophagy 2008;4:1086-9. DOI: 10.4161/auto.7138.
14. Nystrom S., Antoine D.J., Lundback P. et al. TLR activation regulates damage-associated molecular pattern isoforms released during pyroptosis. Embo J 2013;32:86-99. DOI: 10.1038/emboj.2012.344.
15. Narayanan K.B., Park H.H. Toll/interleukin-1 receptor (TIR) domain-mediated cellular signaling pathways. Apoptosis 2015;20(2):196—209. DOI: 10.1007/s10495-014-1073-1.
16. Eriksson M., Pena-Martinez P., Ramakrishnan R. et al. Agonistic targeting of TLR1/TLR2 induces p38 MAPK-dependent apoptosis and NFKB-dependent differentiation of AML cells. Blood Adv 2017;1(23):2046—57. DOI: 10.1182/bloodadvances.2017006148.
17. Sipos F., Kiss A.L., Constantinovits M. et al. Modified genomic self-DNA influences in vitro survival of HT29 tumor cells via TLR9-and autophagy signaling. Pathol Oncol Res 2018. DOI: 10.1007/s12253-018-0544-z.
18. Szczepanski M.J., Czystowska M., Szajnik M. et al. Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res 2009;69(7):3105—13. DOI: 10.1158/0008-5472.CAN-08-3838.
19. Yang H., Zhou H., Feng P. et al. Reduced expression of Toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion. J Exp Clin Cancer Res 2010;29(1):92. DOI: 10.1186/1756-9966-29-92.
20. Cherfils-Vicini J., Platonova S., Gillard M. et al. Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J Clin Invest 2010;120(4):1285—97. DOI: 10.1172/JCI36551.
21. Sheyhidin I., Nabi G., Hasim A. et al. Overexpression of TLR-3, TLR-4, TLR-7 and TLR-9 in esophageal squamous cell carcinoma. World J Gastroenterol 2011;17(32):3745—51. DOI: 10.1007/s00262-011-1057-8.
22. Saint-Jean M., Knol A.C., Nguyen J.M. et al. TLR expression in human melanoma cells. Eur J Dermatol 2011;21(6):899—905. DOI: 10.1684/ejd.2011.1526.
23. Petricevic B., Vrbanec D., Jakic-Razumovic J. et al. Expression of Toll-like receptor 4 and beta 1 integrin in breast cancer. Med Oncol 2012;29(2):486—94. DOI: 10.1007/s12032-011-9885-0.
24. Ye K., Wu Yi., Sun Ya. et al. TLR4 siRNA inhibits proliferation and invasion in colorectal cancer cells by downregulating ACAT1 expression. Life Sciences 2016;155:133—9. DOI: 10.1016/j.lfs.2016.05.0120024-3205.
25. Bianchi F., Pretto S., Tagliabue E. et al. Exploiting poly (I : C) to induce cancer cell apoptosis. Cancer Biol Ther 2017;18(10):47—756. DOI: 10.1080/15384047.2017.1373220.
26. Haining W.N., Davies J., Kanzler H. et al. CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans. Clin Cancer Res 2008;14(17):5626—34. DOI: 10.1158/1078-0432.CCR-08-0526.
27. Katsuda M., Iwahashi M., Matsuda K. et al. Peptide vaccine therapy with TLR-9 agonist for patients with esophageal squamous cell carcinoma. Gan to Kagaku Ryoho 2011;38(12):1942—4.
28. Rapoport A.P., Aqui N.A., Stadtmauer E.A. et al. Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells. Clin Cancer Res 2014;20(5):1355—65. DOI: 10.1158/1078-0432.CCR-13-2817.
29. Volkov M.Yu. Role of Toll-like receptors and their endogenous ligands in the pathogenesis of rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice 2016;54(1):78—85 (In Russ.).
30. Weigel B.J., Cooley S., DeFor T. et al. Prolonged subcutaneous administration of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies. Am J Hematol 2012;87(10):953—6. DOI: 10.1002/ajh.23280.
31. Kazma R., Mefford J.A., Cheng I. et al. Association of the innate immunity and inflammation pathway with advanced prostate cancer risk. PLoS One 2012;7(12):51680. DOI: 10.1371/journal.pone.0051680.
32. Li C., Li H., Jiang K. et al. TLR4 signaling pathway in mouse Lewis lung cancer cells promotes the expression of TGF-p1 and IL-10 and tumor cells migration. Biomed Mater Eng 2014;24(1):869—75. DOI: 10.3233/BME-130879.
33. Zhang X., Xu J., Ke X. et al. Expression and function of Toll-like receptors in peripheral blood mononuclear cells from patients with ovarian cancer. Cancer Immunol Immunother 2015;64(3):275—86. DOI: 10.1007/s00262-014-1632-x.
34. Palani C.D., Ramanathapuram L., Lam-Ubol A., Kurago Z.B. Toll-like receptor 2 induces adenosine receptor A2a and promotes human squamous carcinoma cell growth via extracellular signal regulated kinases 1/2. Oncotarget 2017;9(6):6814—6829. DOI: 10.18632/oncotarget.23784.
35. Liang P., Guo J., Li S. et al. Prevention of prostate tumor development by stimulation of antitumor immunity using a standardized herbal extract (Deep Immune®) in TRAMP mice. Evid Based Complement Alternat Med 2018:9707543. DOI: 10.1155/2018/9707543.
36. Geller M.A., Cooley S., Argenta P.A. et al. Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers. Cancer Immunol. Immunother 2010;59(12):1877—84. DOI: 10.1007/s00262-010-0914-1.
37. Falke J., Lammers R.J., Arentsen H.C. et al. Results of a phase 1 dose escalation study of intravesical TMX-101 in patients with nonmuscle invasive bladder cancer. J Urol 2013;189(6):2077—82. DOI: 10.1016/j.juro.2012.11.150.
38. Isambert N., Fumoleau P., Paul C. et al. Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with re-fractory solid tumors. BMC Cancer 2013;13:172. DOI: 10.1186/1471-2407-13-172.
39. Kaczanowska S., Joseph A.M., Davila E. TLR agonists: our best frenemy in cancer. Immunotherapy J Leukoc Biol 2013;93:847-63. DOI: 10.1189/jlb.1012501.
40. Shi M, Chen X, Ye K. et al. Application potential of toll-like receptors in cancer immunotherapy: Systematic review. Medicine (Baltimore) 2016;95(25):3951. DOI: 10.1097/MD.0000000000003951.
41. Tsan M.F., Gao B. Heat shock proteins and immune system. J Leukoc Biol 2009;85(6):905-10. DOI: 10.1189/jlb.0109005.
42. Lazanovich V.A., Markelova E.V., Smirnov G.A., Smolina T.P. Clinical significance of Toll2, Toll4, CD14, and HLA-DR expression on the monocytes in patients with sepsis. Meditsinskaya immunologiya = Medical Immunology 2015;17(3):221—8 (In Russ.).
43. Baryshnikova M.A.. Kosorukov V.S. Cancer vaccine adjuvants Rossiyskiy bioterapevticheskiy zhurnal = Russian Journal of Biotherapy 2018;17(4):36—44. (In Russ.).
44. Berezhnaya N.M. Toll-like receptors and oncogenesis. Onkologiya = Oncology 2013;15(2):76—86 (In Russ.).
45. Stone G.W., Barzee S., Snarsky V. et al. Nanoparticle-delivered multimeric soluble CD40L DNA combined with Toll-Like Receptor agonists as a treatment for melanoma. PLoS One 2009;4(10):7334. DOI: 10.1371/journal.pone.0007334.
46. Ghochikyan A., Pichugin A., Bagaev A. et al. Targeting TLR-4 with a novel pharmaceutical grade plant derived agonist, Immunomax®, as a therapeutic strategy for metastatic breast cancer. J Transl Med 2014;12:322. DOI: 10.1186/s12967-014-0322-y
47. Klein J.C., Moses K., Zelinskyy G. et al. Combined toll-like receptor 3/7/9 deficiency on host cells results in T-cell-dependent control of tumour growth. Nat Commun 2017;8:14600. DOI: 10.1038/ncomms14600.
48. Zahm C.D., Colluru V.T., McIlwain S.J. et al. TLR Stimulation During T-cell Activation Lowers PD-1 Expression on CD8+ T Cells. Cancer Immunol Res. 2018;6(11):1364—74. DOI: 10.1158/2326-6066.CIR-18-0243.
49. Bhatia S., Miller N.J., Lu H. et al. Intratumoral G100, a TLR4 agonist, induces antitumor immune responses and tumor regression in patients with Merkel cell carcinoma. Clin Cancer Res 2018. DOI: 10.1158/1078-0432.CCR-18-0469.
50. Rubina K.A., Surkova E.I., Semina E.V. et al. T-Cadherin Expression in Melanoma Cells Stimulates Stromal Cell Recruitment and Invasion by Regulating the Expression of Chemokines, Integrins and Adhesion Molecules. Cancers (Basel) 2015;7(3):1349—70. DOI: 10.3390/cancers70308400.
51. Florea I.D., Karaoulani Ch. Epigenetic Changes of the Immune System with Role in Tumor Development. Ch.11. In: Cancer Epigenetics for Precision Medicine: Methods and Protocols, Methods in Molecular Biology. Eds.: R.G. Dumitrescu, M. Verma, Springer Science + Business Media, LLC. 2018;1856:203—17. DOI: 10.1007/978-1-4939-8751-1_11.
52. Tang Y.M., Cao Q.Y., Guo X.Y. et al. Inhibition of p38 and ERK1/2 pathways by Sparstolonin B suppresses inflammation-induced melanoma metastasis. Biomed Pharmacother 2018;98:382—9. DOI: 10.1016/j.biopha.2017.12.047.
53. Tartey S., Takeuchi O. Pathogen recognition and Toll-like receptor targeted therapeutics in innate immune cells. Int Rev Immunol 2017;36(2):57—73. DOI: 10.1080/08830185.2016.1261318.
Review
For citations:
Treshalina E.M., Mikhaylova I.N., Kiselevskiy M.V. The different roles of toll-like receptors in oncotherapy. Russian Journal of Biotherapy. 2019;18(3):15-22. (In Russ.) https://doi.org/10.17650/1726-9784-2019-18-3-15-22
Views:
438
Email this article 
